Both CYP2C9-NM and IM responded to treatment with a significant improvement in anxiety and depression symptoms (p < 0.001), and CYP2C9-PM experienced a mild, non-significant improvement in both depression and anxiety HDRS and HARS scores, respectively (Table 3; Figure 7). The gene discussed is CYP2C9; the disease is depressive symptom measurement.